Clinical Protocol SeCore, uTYPE and 3500 Dx System

NCT01285427 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 300

Last updated 2014-04-17

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to compare the Invitrogen SeCore(R) sequencing system and uTYPE(R) interpretation software to the predicate device Invitrogen SSP UniTray(R) with UniMatch(R) interpretation software and show 95% concordance with 90% confidence.

Conditions

  • Human Leukocyte Antigens (HLA)

Sponsors & Collaborators

  • Life Technologies Corporation

    lead INDUSTRY

Principal Investigators

  • Deanna Vella · Life Technologies

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2011-01-31
Primary Completion
2011-06-30
Completion
2011-06-30

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01285427 on ClinicalTrials.gov